Bicara Therapeutics Inc. Common Stock (BCAX)
Largest Insider Buys in Sector
BCAX Stock Price History Chart
BCAX Stock Performance
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Insider Activity of Bicara Therapeutics Inc. Common Stock
Over the last 12 months, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $0 worth of Bicara Therapeutics Inc. Common Stock stock.
On average, over the past 5 years, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $857.84M. Flynn James E (Possible Members of 10% Group) — $23.94M.
The last purchase of 35,000 shares for transaction amount of $630,000 was made by Flynn James E (Possible Members of 10% Group) on 2024‑09‑17.
List of Insider Buy and Sell Transactions, Bicara Therapeutics Inc. Common Stock
| 2024-09-17 | Possible Members of 10% Group | 35,000 0.045% | $18.00 | $630,000 | -6.02% | |||
| 2024-09-16 | 1.83M 2.6517% | $18.00 | $32.99M | +0.18% |